Climb Bio CLYM
NASDAQ CLYM
$11.50 -0.24 (-2.04%)
At close: Sep 29, 2026 · 4:00 PM EDT

Climb Bio (CLYM) Restructuring Costs (2023 - 2024)

Updated

Climb Bio (CLYM) recorded Restructuring Costs of -$3.36 million in Q4 2024, compared with $4.13 million a year earlier.

Analysis

Climb Bio (CLYM) Restructuring Costs (2023 - 2024) Analysis & Trends

For FY2024, Climb Bio reported Restructuring Costs of $3.36 million, down 91.1% from FY2023.

  • Across earlier years, Restructuring Costs came in at $37.62 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Climb Bio 894.05 Mn 894.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -3.36 Mn
Sep 30, 2024 6.68 Mn
Dec 31, 2023 4.13 Mn
Sep 30, 2023 444,000.00
Jun 30, 2023 1.47 Mn
Mar 31, 2023 31.57 Mn
API Access

Climb Bio Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=CLYM&period=max&api_key=YOUR_API_KEY